2 hours NovoCure (NASDAQ:NVCR) Raised to “Buy” at HC WainwrightMarketBeat
HC Wainwright raised shares of NovoCure from a “neutral” rating to a “buy” rating and lifted their price target for the company from $24.00 to $30.00 in a research report on Wednesday.
X